PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that it is one of 54 companies approved to share the $60 million allocation through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2014. Each of the 54 selected companies is expected to receive approximately $1.1 million which is a 21% increase from last year.
Help employers find you! Check out all the jobs and post your resume.
